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What is already known about this topic? 29 
 Prenatal WES for genetic diagnosis is possible, but little is known regarding 30 
parental experiences of prenatal sequencing   31 
What does this study add? 32 
 Parents require specific information to help them decide whether to undergo 33 
WES for prenatal diagnosis 34 
 Appropriate counselling is essential for informed consent 35 
 Parents require explanation about what WES might identify, and how and 36 
when findings are returned   37 
Abstract 38 
Objective 39 
To explore parental experiences of WES for prenatal diagnosis, and ascertain what 40 
influenced their decision-making to undergo testing.  41 
Method 42 
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Twelve women comprised a purposeful sample in a series of semi-structured 43 
interviews.  All had received a fetal anomaly diagnosis on ultrasound.  A topic guide 44 
was used, and transcripts were thematically analysed to elicit key themes.   45 
Results 46 
Five main themes (parental experiences of prenatal WES, need for information, 47 
consent/reasons for prenatal WES, sources of support for prenatal WES, and return 48 
of WES findings to families) emerged, some with multiple sub-themes.   49 
Conclusions 50 
Parents desired as much information as possible and appreciated information being 51 
repeated, and provided in various formats.  Many struggled with clinical uncertainty 52 
relating to the cause and prognosis following a fetal anomaly diagnosis, and found it 53 
difficult to balance the risks of invasive testing against their need for more definitive 54 
information.  Parents trusted their clinicians and valued their support with decisions 55 
in pregnancy.  Testing was sometimes pursued to reassure parents that their baby 56 
was ‘normal’ rather than to confirm an underlying genetic problem.  Parents were 57 
motivated to undergo WES for personal and altruistic reasons but disliked waiting 58 
times for results, and were uncertain about what findings might be returned.           59 
Key words: Prenatal; whole exome sequencing; parents views 60 
Introduction 61 
Structural anomalies are diagnosed by ultrasound in up to 3% of pregnancies[1].  62 
Fetal outcome is variable depending on the type of abnormalities identified, and the 63 
underlying genetic aetiology[2].  Determining the potential cause of fetal anomalies 64 
enables a more accurate diagnosis and provides prognostic information relating to 65 
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the pregnancy and the likely risk of recurrence [2].  Genetic testing is available for 66 
parents following the identification of a fetal anomaly and recent advances in 67 
molecular genetics are enabling increasingly detailed prenatal genetic 68 
investigation[3].  Prenatal genetic diagnosis is of significant value to parents and can 69 
assist with prospective planning for optimal perinatal management[4].  It may also 70 
provide a means to inform parental decisions regarding the continuation or 71 
termination of an affected pregnancy.  Currently in the UK prenatal genetic testing 72 
involves increasingly routine QF-PCR (Quantitative Fluorescence-Polymerase Chain 73 
Reaction) and CMA (Chromosomal Microarray) to identify chromosomal differences 74 
and variations in copy number (CNVs).  Targeted genetic sequencing of exonic 75 
regions is used to detect single nucleotide variants (SNVs) associated with various 76 
single gene disorders, but this modality has limited potential to identify CNVs.   77 
Whole genome sequencing (WGS) approaches are beginning to be used and have 78 
the ability to detect CNVs.  79 
 Next-Generation Sequencing (NGS) and the Prenatal Application of Whole 80 
Exome Sequencing (WES) Approaches  81 
NGS applications are broadening the scope of prenatal diagnosis to identify the 82 
genetic aetiology of sporadic and inherited disease[5] and are revolutionising current 83 
practice in prenatal diagnostics[6].  Sequencing analysis of trio (fetal and biparental) 84 
DNA can identify genetic alterations that are potentially causative of fetal 85 
abnormalities, but this technology is only recently being evaluated within prenatal 86 
medicine.  WES captures the majority of regions that encode proteins to identify 87 
SNVs and small insertions and deletions (indels)[5].   As a technique it has proved 88 
useful to the diagnosis of known genetic disease and to the discovery of novel 89 
  5 
 
disorder genes,[7]  and is increasingly being used to diagnose rare Mendelian 90 
conditions (when standard tests are uninformative)[8].  The use of WES in prenatal 91 
diagnosis is potentially advantageous as its accuracy enables personalised care, 92 
prospective risk assessment and preventative fertility treatment, reproductive genetic 93 
counselling and family planning[9].  As such, if a definitive diagnosis is made this 94 
testing may aid understanding of aetiology, potential co-morbidities and risk of 95 
recurrence.  However, NGS, in the prenatal setting, presents potential challenges 96 
around the interpretation of results, especially if positive results are not thought to be 97 
‘causative’ or are of unknown significance.  The detection of these secondary and/or 98 
incidental findings (ICFs), may have significant and morbid emotional effects on the 99 
parents and also impact negatively on parental decision making in the prenatal 100 
setting.     101 
Several studies involving WES in patients with Mendelian disease have 102 
demonstrated a diagnostic yield in the order of 25%[10-11]. This indicates that WES is 103 
complementary to conventional prenatal diagnostic techniques[12].  Research relating 104 
to the use of genetic sequencing for prenatal diagnosis in on-going pregnancy is 105 
limited,[4] however, the feasibility of WES in prenatal diagnostics has been 106 
demonstrated in small case series[3,12,13].  Survey data involving 186 expectant 107 
parents in the USA demonstrated that 83% thought that prenatal WES should be 108 
offered,[14] and research into the views of fifteen women with non-continuing 109 
anomalous pregnancies found that they had high hopes and expectations of WES, 110 
despite testing enabling a diagnosis in only 1 in 3 (30% of cases)[15].   111 
Successful implementation of WES for prenatal diagnosis would require rigorous 112 
health economic assessment, and would be dependent upon the development of 113 
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rapid analytical and interpretation pipelines[12].  Sequencing findings would need to 114 
be available within a timeframe that would assist parents to make informed decisions 115 
relating to the affected pregnancy, and this will only be possible when the knowledge 116 
base relating to the genetic causes of prenatal structural anomalies is significantly 117 
developed[12].  The challenge of prenatal WES will be the integration of sequencing 118 
analysis into prenatal diagnostics as part of a responsible and ethical framework for 119 
clinical practice[2].  Currently, the PAGE consortium project funded by the Department 120 
of Health/Wellcome Trust is prospectively recruiting parent/fetus trios across the UK 121 
to investigate the prenatal use of WES as a diagnostic tool in structurally abnormal 122 
fetuses[16].  The study will analyse ~1000 trio whole exomes with the aim to elucidate 123 
the relative contribution of different forms of genetic variation to prenatal structural 124 
anomalies. 125 
As the use of WES increases, and transfers from the research setting to routine 126 
care, it will be important to ensure a streamlined approach to the integration of 127 
genomic analysis to existing prenatal care pathways.  This transition will require an 128 
understanding of parental acceptability and expectations around sequencing 129 
analysis for prenatal diagnosis following discussion with parents who have personal 130 
experience of this type of genetic testing in pregnancy.  These parents will provide a 131 
unique perspective on their experiences as it is important to ensure that this 132 
technology is translated into clinical care because parents consider it to be of value.  133 
The views of parents who have undergone genetic sequencing for prenatal diagnosis 134 
have not been formally explored using qualitative interview methodology.  The aim of 135 
this research was to gain insight into the experience of parents who have undergone 136 
prenatal WES following a fetal anomaly diagnosis, to understand more about what 137 
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influenced their decision-making to have testing, and elicit their beliefs around how 138 
they perceived WES to be of potential benefit.  Qualitative methods allow for 139 
exploration of parental experiences, beliefs and feelings around the use of prenatal 140 
WES in a way that quantitative methodology cannot.  It is important to understand 141 
parental views around prenatal sequencing to inform the routine use of these 142 
technologies in the future.   143 
Method 144 
A purposeful sample[17] (i.e. parents who had undergone WES for prenatal diagnosis 145 
following enrolment in the PAGE Study[16]) was selected to participate in this 146 
research.  All parents had received focussed pre-test counselling for approximately 147 
one hour from a fetal medicine specialist regarding standard invasive prenatal testing 148 
options (QF-PCR and CMA), non-invasive prenatal testing (NIPT) for common 149 
aneuploidy, and WES as part of the PAGE Study.  All were informed prior to testing 150 
that trio analysis (biparental/fetus) would be performed and that results would not be 151 
available within the timeframe of their pregnancy.  It was also explained that only 152 
pathological findings considered to have contributed to the fetal phenotype would be 153 
returned, and that no uncertain, secondary or incidental information would be 154 
reported.  They were also told that WES could potentially detect up to 10% more 155 
causes for fetal structural anomalies above standard testing based on exiting 156 
evidence.  Fifteen women were approached at random by EQJ (research midwife) 157 
during their appointments at the Birmingham Women’s Hospital Fetal Medicine 158 
Centre and asked to participate in an interview, three of whom declined without 159 
giving a reason, thus the study sample composed twelve women (Figure 1).  It was 160 
anticipated that if data saturation was not reached after twelve interviews then more 161 
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interviews would continue until data saturation was achieved.  Interviews were 162 
undertaken either at the hospital or at home depending on parental preference.  A 163 
topic guide was used to guide questioning, and interviews were carried out by EQJ 164 
with each interview lasting approximately 30 to 45 minutes.  Development of the 165 
topic guide was informed by related focus group research with stakeholders 166 
undertaken by EQJ and others[18].  Women were interviewed alone, or with their 167 
partner/or other close family member.  All women spoke English although this was 168 
not a criterion for inclusion.  The timing of interviews varied, but all were carried out 169 
within two weeks of parents giving consent for WES.  Issues explored with parents 170 
included their personal experience of prenatal genetic testing and diagnosis, and 171 
what they remembered and understood regarding WES.  Parents were asked about 172 
their expectations and concerns relating to prenatal genetic sequencing, and about 173 
the factors that influenced them to undergo testing, including the information they 174 
required to inform their decision.  Interviews were digitally recorded and transcribed.  175 
National Research Ethics Service approval to undertake this study was granted by 176 
West Midlands - South Birmingham Committee (REC Reference 14/WM/0150).   177 
Analysis 178 
Analysis of the interview data followed a standard thematic approach[19].  Transcripts 179 
were read by EQJ to enable familiarisation.  Using an inductive process[20] the 180 
transcripts were then coded for similarities and differences in content to develop a 181 
coding frame.  Encompassing key themes with underpinning sub-themes were 182 
produced by combining the identified codes.  Two transcripts were independently 183 
read by SCH (clinical co-facilitator for aforementioned focus groups and interview 184 
design) who similarly used thematic analysis to elicit themes[19].  The coding frame 185 
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developed by EQJ was shared with SCH and was subsequently modified.  The 186 
coding frame and agreed themes were shared with SMG (medical sociologist).  Two 187 
further transcripts were analysed by SMG using the established coding frame.  188 
Further amendments to the coding frame were not thought necessary as a result of 189 
this analysis.  All three researchers met to reach a consensus that the themes 190 
identified were indeed reflective of the accounts provided.  A rapid analysis of the 191 
interview transcripts was then undertaken by EQJ to ensure completeness and 192 
assess for data saturation[19].  A consensus decision by the three researchers was 193 
made that data saturation had occurred and that no further interviews were required.   194 
Results 195 
Participants were diverse with regard to age, ethnicity, parity and gestation, and had 196 
varying diagnoses of both isolated and multiple fetal structural anomalies (Figure 1).  197 
Women were aged between 21 and 38, and identified themselves as Caucasian, 198 
Black African or Asian, with Caucasian women comprising 75% of the sample.  Of 199 
the 12 women interviewed 7 (58%) were multiparous and gestational ages ranged 200 
from 12 to 38 weeks.  There was an equal split between isolated and multiple 201 
structural abnormalities and the prognosis for fetuses were variable and sometimes 202 
uncertain.      203 
Five main themes emerged some with multiple sub-themes (Figure 2).    204 
Theme One: Parental experiences of prenatal WES   205 
Parents sometimes struggled to balance the risks of invasive testing against the 206 
perceived benefit of receiving a genetic diagnosis, particularly if there was 207 
uncertainty relating to the ultrasound features and the prognosis for the baby (this 208 
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was especially true if there was a previous history of miscarriage and any associated 209 
traumatic memories)   210 
“It was more the risk factor because I had a miscarriage last year and it was 211 
really horrible so we didn’t want to go through that again, especially as I was 212 
well over 20 weeks and into my second trimester and the baby was fully 213 
formed, so that was quite worrying but it wasn’t so much for the results” 214 
(Interview 4 – Mother) 215 
Parents felt shocked when first told that their baby had a congenital difference, but 216 
this initial shock was often replaced with on-going anxiety.  Some said it felt as 217 
though a ‘heavy weight’ had been placed upon them, and found the experience to be 218 
extremely scary.  Parents appeared to worry more about the uncertain prognosis for 219 
the baby and less about the genetic findings that testing might identify.  Many 220 
remembered feeling overwhelmed by the different tests available, and felt that their 221 
worries and concerns were compounded because they had so much to think about 222 
at the time: 223 
“It was scary to be honest with you, all the different tests and constant worry.  224 
It was worrying because we didn’t know what she (baby) would look like or 225 
anything like that” (Interview 2 – Father) 226 
Self-blame that they had done something to have caused the fetal anomaly was a 227 
common parental concern, thus a desire for reassurance that this was not the case 228 
was reported.  All parents described that they trusted their clinicians and valued 229 
receiving their clear explanations.  Parents described that they were assisted in their 230 
decision-making when they felt supported by clinicians, and believed that any 231 
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prenatal testing options discussed by the consultant overseeing their care would be 232 
relevant and useful which reassured them: 233 
“We thought that it would give us some reassurance and help us plan and 234 
prepare for the future” (Interview 4 – Father) 235 
Some parents described how they tried to remain hopeful for a good pregnancy 236 
outcome, but also felt that they would love the baby regardless of any disability they 237 
may have.  Some remembered consciously blocking out their concerns in an attempt 238 
to keep positive, believing that searching out more information would only serve to 239 
exacerbate their worry.  When faced with various options, parents felt that they could 240 
make difficult decisions if they were not pressurised and were given enough time: 241 
“I think we’ve tried to blank quite a lot of it because we don’t want to be 242 
negative.  When she is here we will cross that path won’t we?” (Interview 2 – 243 
Mother)     244 
Theme Two: Need for information  245 
A desire for information to understand more about the anomaly affecting their baby 246 
and the different testing and treatment options available was universally reported by 247 
parents.  Parents needed to ask lots of questions of their clinicians as they tried to 248 
balance the pros and cons of testing: 249 
 “More information is all good because it helps us understand whatever it is.  250 
You can prepare yourself and your family and do what you possibly can with 251 
the information that you are given” (Interview 1 – Father)  252 
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A need for repetition of complex information was also evident as parents found it 253 
difficult to fully understand everything that they were told at the initial consultation.  254 
Discussion and explanation on more than one occasion was found to be helpful, and 255 
parents appreciated receiving clinical details in written format relating to the specific 256 
anomalies identified:  257 
“Some things you don’t understand, some of the things the doctor says”  258 
(Interview 2 – Mother)   259 
“But when they break it down into smaller (pieces), all these big words like, 260 
and obviously we don’t know what they mean, but they do break it down”              261 
(Interview 2 – Father)  262 
Theme Three: Consent and reasons for prenatal WES 263 
Desiring more information and a wish to rule out as much as possible was a key 264 
motivator for parents to undergo prenatal testing.  Parents perceived WES as a more 265 
detailed assessment to find out additional genetic causes for the anomalies affecting 266 
their baby that are not tested for routinely.  They considered more information to be 267 
the best thing for parents and the baby and this was often the main reason for 268 
testing: 269 
 “It was going to test for more than everything else, and if there was anything 270 
rare that it is more likely to pick that up, and he explained that it will take much 271 
longer” (Interview 10 – Mother) 272 
Parents were aware that testing involved looking for differences and similarities 273 
between their individual DNA and the DNA of their baby.  It was understood that the 274 
testing would not benefit the current pregnancy (because results would not be 275 
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reported back within the timeframe of pregnancy), but thought that it may be helpful 276 
for the baby when older, or if it could provide information for future pregnancy 277 
planning:    278 
 “It was to try and work out if there is anything between us (parents) that has 279 
caused the anomalies.  I do not know whether it searches for one or both or 280 
whatever, but just that it is trying to find out if there is anything that is within 281 
either of us that has made these things happen in the baby” (Interview 3 – 282 
Mother) 283 
Parents were sometimes uncertain about what was actually being tested for or ruled 284 
out and would have appreciated hearing about some example conditions.  Most felt 285 
that it was better to know about any genetic causes and hoped that the testing would 286 
provide answers which would be reported back to them:    287 
 “I would like to know about what other things they test for because I asked 288 
them and they said they would test for over 200 things but I would have liked 289 
examples because that was still worrying me” (Interview 5 – Mother) 290 
Parents described their decision to have prenatal WES as an opportunity to help 291 
others in the future.  Altruistic motivations involved feeling that it was important to 292 
gather more information on the genetic causes of fetal anomalies, and viewed their 293 
participation as a means to contribute to research and the progression of medical 294 
knowledge:   295 
“I was kind of contributing to something really, to help others in the future.  It is 296 
the only way you are going to learn and evolve in the medical field.  If you can 297 
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achieve anything with it then I would be more than happy” (Interview 7 – 298 
Mother) 299 
Theme Four: Sources of support for prenatal WES 300 
Electronic and written sources of support were helpful to parents when faced with the 301 
decision of whether to undergo prenatal sequencing.  Many opted to avoid the 302 
internet due to a perceived risk of inaccurate information.  Parents felt that some 303 
internet sources showed the extremes of disease and were not always relevant.  304 
Some accessed NHS websites and Wikipedia feeling that these were more 305 
trustworthy sources.  Information leaflets on specific conditions were generally found 306 
to be helpful:   307 
 “We got advice before we came here as well to steer clear of the internet 308 
because obviously you get a lot of misinformation, so I kind of took that to 309 
heart as it sounded quite sensible so I have not really been googling” 310 
(Interview 1 – Father) 311 
Interactive sources of support were reported to be helpful and parents valued being 312 
able to ask questions directly.  One couple described that they would have liked to 313 
speak to other parents with similar experiences, suggesting that a workshop where 314 
they could find out more information and ask questions could be a forum for this:  315 
 “Maybe a workshop held by the hospital or midwife that is solely dedicated to 316 
this as part of their job, where they would have all the knowledge and can 317 
educate families, and where parents can come together and share their 318 
experiences” (Interview 4 – Father)  319 
Theme Five: Return of prenatal WES findings to families 320 
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Presently, the prenatal WES ‘clinical pipeline’ within the PAGE Study[16] takes up to 321 
twelve months.  The delay in receiving results was felt by some parents to have 322 
prolonged their worry and anxiety.  Parents still wished to have WES even though 323 
they knew that there would be a significant wait for results believing that they would 324 
still rather know than not know about any relevant genetic findings.  Many described 325 
that having this information eventually would help their understanding and better 326 
equip them to cope and prepare for any challenges ahead.  Some felt that more 327 
information in time relating to the risk of recurrence was worth waiting for and would 328 
possibly assist them with future pregnancy planning: 329 
“That was what I hated, just waiting (for results)” (Interview 5 – Mother) 330 
Some parents were uncertain regarding the process by which results would be 331 
returned and would have appreciated having this better explained to them.  Some 332 
parents preferred to return to the hospital and have the results explained by familiar 333 
clinicians face-to-face.  All were happy for their information to be stored and shared 334 
with other clinicians and researchers involved in prenatal diagnosis, and although 335 
some said that they preferred their personal information to be anonymised, others 336 
were less concerned about protecting their identity: 337 
 “If there was anything (genetic results) we would like to come back here 338 
(hospital) and sit down and discuss it face-to-face with you guys (medical 339 
team) because we are comfortable with you” (Interview I – Mother) 340 
Conclusions 341 
This is the first qualitative interview study exploring parental experiences of WES for 342 
prenatal diagnosis.  The findings are important because they are novel in this context 343 
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and contribute to a limited body of evidence relating to parental experiences of 344 
prenatal sequencing in structurally abnormal fetuses.  Given the potential for NGS 345 
techniques to detect genetic alterations that are causative of various developmental 346 
fetal anomalies, it is likely that prenatal sequencing will be integrated into existing 347 
prenatal care pathways in the foreseeable future.  Transition from the research 348 
setting to the clinic will require an assessment of the acceptability of prenatal 349 
sequencing for genetic diagnosis to evaluate if testing is desirable to parents.  This 350 
research has highlighted the views of parents who have undergone WES for prenatal 351 
diagnosis, and provided insight in to their decision-making to proceed with testing, 352 
and what they perceived the potential benefits of WES to be.  Facilitating appropriate 353 
consent for testing was highlighted by parents as extremely important, who felt that 354 
they needed clearer information regarding what WES might identify, and what, when 355 
and how results would be returned.  If WES is to be routinely available for prenatal 356 
diagnosis this will require the development of national and international guidance 357 
that encompass the consent procedure, as well as the option for parents to opt in or 358 
out of receiving information which is not directly related to the prenatal findings (i.e. 359 
the primary indication for testing) both for the unborn baby and for themselves[13].  360 
Inevitably, prenatal WES and the interpretation of results will become more rapid and 361 
clinical usefulness will be significantly improved.  Likewise, contribution of parental 362 
views around prenatal WES will assist with streamlining the clinical use of the 363 
technology for diagnostic purposes.  However, CMA research indicates that variants 364 
of uncertain significance (VUS) may continue, in a small number of cases, to have 365 
morbid emotional consequences[21,22].  The need for public debate around the use 366 
and potential benefits, as well as the drawbacks of prenatal genetic diagnosis is 367 
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clear, to facilitate the general acceptance and integration of sequencing techniques 368 
into routine prenatal care[23]. 369 
Limitations 370 
It is acknowledged that the views expressed by some parents (such as the need for 371 
more information to balance risks, feelings of self-blame, and consciously blocking 372 
out concerns to remain positive), are likely to be applicable to any couple whose 373 
baby has ultrasonographically detected fetal anomalies irrespective of whether they 374 
decide to undergo prenatal testing (including WES).  As such, these particular 375 
findings are not necessarily unique in this context.  This research explored the 376 
experience of parents who underwent WES for prenatal diagnosis at one large UK 377 
fetal medicine centre and parents at other centres (within the UK or internationally) 378 
may have different views.  The opinions of parents who declined WES are similarly 379 
not well represented.  It cannot be assumed therefore that the findings are applicable 380 
to all parents; moreover they may not reflect the views of parents who decline 381 
genetic diagnosis using invasive methods.  Further research that considers the 382 
opinions of parents who decline prenatal sequencing is needed.  Ethical approval for 383 
the PAGE Study[16] only permitted the return of results to families considered to be 384 
pathogenic and contributing to the prenatal phenotype, thus it was not possible to 385 
explore parental views around the return of VUS and ICFs.  Parental opinions 386 
regarding the return of VUS and ICFs will be explored in a planned further phase of 387 
work.          388 
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